GlassScriptPhysician profile
Steven L Bouldin
NPI 1669799532
$7,703.73
in general payments reported to CMS, 2019-2025
31 companies · $2,983 in 2025
The $2,983 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,954 · 2024: $2,767 · 2025: $2,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,639 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,638.74 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $925.37 | 2023-2025 | Vraylar, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $851.15 | 2023-2025 | Rexulti |
| Pfizer INC. | $712.23 | 2023-2025 | |
| Novo Nordisk INC | $677.23 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $576.66 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $462.09 | 2023-2025 | Xifaxan, Trulance |
| Amgen INC. | $426.14 | 2023-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $418.20 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $373.64 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $275.90 | 2024-2025 | Caplyta |
| Dynavax Technologies Corporation | $264.67 | 2024-2025 | Heplisav-B |
| Astellas Pharma US INC | $209.04 | 2023-2025 | Veozah |
| Axsome Therapeutics, INC. | $198.95 | 2023-2025 | Auvelity, Sunosi |
| Shield Therapeutics INC | $182.04 | 2023-2025 | Accrufer |
| Antares Pharma, INC. | $165.19 | 2023-2025 | Xyosted, Nocdurna, Tlando |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $159.33 | 2023-2025 | Vyepti, Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $120.25 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.44 | 2023-2025 | Jardiance, Synjardy, Ofev |
| Exact Sciences Corporation | $92.12 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $91.70 | 2023-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $72.31 | 2025 | Voquezna |
| Esperion Therapeutics, INC. | $70.27 | 2023-2025 | Nexletol |
| Azurity Pharmaceuticals, INC. | $60.12 | 2023-2025 | Azmiro, Edarbi, Edarbi |
| Merck Sharp & Dohme LLC | $49.52 | 2023 | Belsomra, Steglatro |
| Inspire Medical Systems, INC. | $47.60 | 2023-2025 | Inspire |
| Impel Pharmaceuticals INC. | $43.75 | 2023 | Trudhesa |
| Eisai INC. | $20.07 | 2024 | |
| Halozyme INC | $18.40 | 2023 | |
| Ibsa Pharma INC. | $17.42 | 2025 | Licart, Flector, Tirosint |
| Ironshore Pharmaceuticals INC. | $15.25 | 2024 | |
| Vanda Pharmaceuticals INC. | $13.68 | 2024 | Hetlioz, Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Bouldin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.